NASDAQ$KLRS
Kalaris Therapeutics Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
AlloVir reported financial results for the first quarter ended March 31, 2022.
AlloVir reported a net loss of $43.9 million, or $0.69 per share, for the first quarter ended March 31, 2022. The company's research and development expenses were $29.1 million, and general and administrative expenses were $14.1 million. As of March 31, 2022, AlloVir had cash, cash equivalents, and marketable securities of $201.4 million.
- Initiated posoleucel registrational study to prevent six devastating viral infections.
- FDA granted RMAT designation to posoleucel for Phase 3 multi-virus prevention indication.
- Progressed enrollment in three Phase 3 studies for posoleucel and a Phase 2 trial for ALVR106.
- Completed enrollment in Phase 2 study of posoleucel for the treatment of BK viremia in kidney transplant patients.
Headline financials
Revenue & EPS history
Allovir · Revenue · Quarterly
$0
Forward guidance
AlloVir continues to expect operating expenses to be in the range of $130 million to $145 million for fiscal year 2022, excluding non-cash stock compensation expenses.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+0.5%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+5.9%
Avg return
30 days after
50%
11 / 22 earnings
Positive
+33.6%
Q2 2022
Best reaction
-23.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | -1.8% | +6.9% | +75.0% | |
| Q2 2025 | -10.9% | +0.4% | +56.2% | |
| Q2 2024 | -3.3% | -5.7% | +75.0% | |
| Q1 2025 | -6.1% | -2.8% | +5.6% | |
| Q4 2025 | -3.4% | +4.2% | -21.2% | |
| Q3 2024 | -23.8% | -23.0% | -37.8% | |
| Q1 2024 | -1.7% | -1.4% | +0.5% | |
| Q4 2023 | +0.7% | +2.5% | +5.5% | |
| Q3 2023 | +9.1% | +9.1% | +27.9% | |
| Q2 2023 | +3.0% | +0.3% | +6.6% | |
| Q1 2023 | +14.2% | +13.0% | +2.6% | |
| Q4 2022 | -6.1% | +5.5% | -30.9% | |
| Q3 2022 | +0.9% | +9.1% | +10.5% | |
| Q2 2022 | +33.6% | +37.7% | +31.7% | |
| Q1 2022 | +0.4% | -23.8% | -25.3% | |
| Q4 2021 | +2.3% | +3.6% | -14.1% | |
| Q3 2021 | -2.3% | -3.0% | -28.9% | |
| Q2 2021 | +6.1% | +0.6% | +0.0% | |
| Q1 2021 | +9.7% | +5.0% | +6.0% | |
| Q4 2020 | +0.5% | -2.5% | -29.4% | |
| Q3 2020 | -0.5% | -6.3% | +24.2% | |
| Q2 2020 | -9.7% | -20.6% | -9.5% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro